Shionogi’s newest antibiotic Fetroja has now earned the FDA’s approval, a big win for patients with certain urinary tract infections with few treatment options. But will a label warning of higher mortality rates than other antibiotics torpedo the drug’s chances
read moreNovartis’ Sandoz doubled down on Japan with a €400 million Aspen deal, as Lupin retreated from the country. Dr. Reddy’s detailed its loss from the U.S. recall of generic Zantac. Aslan’s lead drug, pan-HER inhibitor varlitinib, failed yet another critical
read moreThe FDA spent a week going through records at the corporate headquarters of Greenbrier International, owner of the nearly 16,000 Dollar Tree and Family Dollar stores. What it found was that the company has used some of the worst FDA
read moreGlaxoSmithKline has been laboring to boost supplies of next-gen shingles vaccine Shingrix, thanks to a speedy launch that bested all expectations. While it’s planning a slight increase next year, the real “step change” will come in 2024 with a brand-new
read moreThe study team will review how current health and social care systems work. More: NIHR-funded research to improve quality of life for elderly Source: News
read moreThe company has also submitted a marketing authorisation application for the drug to the European Medicines Agency. More: FDA ‘yes’ for Fetroja Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals